Plain-language summaries of the literature behind every protocol.

The strongest criticism of the compounded-peptide expansion is not that these substances are dangerous — it is that if they were, we would have no reliable way to find out. Health-policy scholars writing in Health Affairs in August 2026 noted that section 503A largely exempts compounded preparations from the systematic adverse-event reporting that applies to approved drugs. Weeks earlier, Georgia inspectors found clinics tracking adverse events not at all. A physician who prescribes these substances explains why he thinks the criticism is correct, what a single practice can and cannot honestly claim to do about it, and the six commitments we have put in writing — including voluntary FDA MedWatch reporting where no obligation attaches.

Search "peptide therapy Chattanooga" and a large share of page one is not medical practices. It is programmatic local SEO — one template deployed across dozens of city subdomains with the city name swapped in, built to capture a phone number and sell it. At least five separate domain networks are running this play on Chattanooga and Knoxville terms as of August 2026. Eight tells that separate a licensed practice from an advertising asset — no named clinician, no street address, no state license, copy that appears verbatim on six other cities' pages — each checkable from your phone in under a minute. Including on us.

Georgia's medical board began unannounced inspections of med spas and IV clinics in 2026. Among what inspectors found: chiropractors offering testosterone and weight-loss treatments, in a state whose chiropractic statute (O.C.G.A. § 43-9-16) does not authorize prescribing or injecting — and expressly bars supplement-recommendation authority from being stretched to cover treatment outside chiropractic scope. A license-by-license table of who may prescribe testosterone in Georgia, the eight holdings of the Board's May 7 IV therapy position statement, and the two questions to ask before anyone injects you. Settled law, not forecasting.

A field guide, built from language currently live on clinic pages across Georgia and Tennessee and quoted exactly. Why "are peptides legal? yes" is a different claim than the truth; why "sourced from a licensed FDA-regulated pharmacy" answers a question nobody asked; why a page stamped "last updated March 2026" is describing a world that no longer exists. Plus a fifth question about membership models that bundle drug quantity as "credits," a sixth about the review-approval clause we found in a live patient agreement — void under the federal Consumer Review Fairness Act — and a seventh on who actually owns the practice, which in Georgia is a corporate-practice-of-medicine question with inspectors attached. No competitor named.

Everyone watches the FDA, whose rulemaking runs 12–24 months. Almost nobody watches the state licensing boards — which act in weeks, against a named license, and already have: summary suspensions over compounded peptides in Ohio, and an Alabama rule that bans non-FDA-approved peptide prescribing outright. Why the telehealth subscription model is the most exposed structure in this market, what boards can reach that the FDA cannot, and three questions that take five minutes. Includes where Limitless stands, by name.

Of seven substances reviewed on July 23–24, 2026, the FDA's advisory committee declined exactly one: DSIP, 6–7–1, from a panel that had spent two days overruling its own staff. It is still advertised in named "sleep blends" within thirty minutes of Dalton — beside CJC-1295, which was never on the docket at all. Why blends are a marketing object rather than a clinical one, why "incredibly safe" is now a harder claim to defend after the hearing than before it, and four questions to ask any peptide clinic. No competitor named.

On July 23–24, 2026 the FDA's advisory committee broke from its own staff and recommended adding six of seven peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — to the 503A bulks list, declining only DSIP. The recorded tallies, why a recommendation is still not a rule, what it means specifically for MOTS-c, and what does and does not change for patients today. Dated and unhyped.

MOTS-c earned a favorable FDA advisory-committee recommendation on July 23, 2026. A physician's evidence-and-positioning read: the mitochondrial AMPK mechanism (strong), the human outcome data (still thin), how Limitless uses it in a metabolic context, sourcing standards, and why a favorable vote is still not a rule. Interested and rigorous, without selling ahead of the data.

A special roundup timed to the July 23–24 FDA peptide meeting. The questions patients actually sent this week — does my protocol change on vote day, how will I find out what the committee decided, why sourcing matters, how to read "FDA rejects" headlines, and whether approved therapies like testosterone and tesamorelin are caught up in the review. Plain answers, nothing designed to sell you.

The first Limitless roundup: real patient questions, anonymized and answered by the physician who reads your labs. Peptide legality before the July 23–24 PCAC vote, TRT and the 2026 cardiovascular data, whether NAD+ is worth it, why tesamorelin leads the GH-axis menu, and daily tadalafil without ED. No marketing fluff, and "we don't know yet" when that's the honest answer.

A GLP-1 drug moves the scale — but a quarter to a third of that weight can be lean muscle, not fat. The 2026 body-composition data (and why tirzepatide loses more muscle than semaglutide), why losing muscle while losing weight is a bad trade, and the protein + resistance + GH-axis protocol Limitless builds around every GLP-1 prescription. The honest version the weight-loss mills skip.

The July review runs two days; day two — sleep (DSIP), cognition (Semax), longevity (Epitalon) — is where the marketing most outruns the human data. An honest, evidence-tiered read on each: what the literature actually shows, why none is a default Limitless protocol, and why a favorable July 24 vote would make a peptide legally compoundable, not clinically warranted. The page for the patient searching “is Semax legit?” and finding only vendor blogs.

A physician-maintained tracker of the July 23–24 FDA compounding review that decides the durable legal status of several peptides we prescribe. Key dates (comment window closes July 22, comments by July 9 reach the committee in advance, meeting July 23–24, second meeting early 2027), the full docket with salt-form nuance, the comment we filed, sourcing and safety, the evidence on each peptide, and a dated update log. One page, updated when the facts change.

A dated, plain-language snapshot of where compounded peptides actually stand in June 2026. The one distinction the headlines keep blurring (a meeting vs. a recommendation vs. a rule), the seven peptides on the July docket (FDA-2025-N-6895) by category, what is not on the docket and why that matters, the second review already signaled for early 2027, and four things a patient should actually do with the news.

The patient version, in four minutes. Does the July meeting change your protocol? (No.) Is your GH-axis therapy affected? (No.) What happens after the vote, what Limitless does, and why a recommendation is not a rule. Calm, accurate answers for current and prospective patients hearing the noise.

A peer-reviewed primer in the American Journal of Sports Medicine covers BPC-157, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. Here is the honest read — and exactly where the peer-reviewed journal article and the standing Limitless posture line up, and where (CJC-1295) they don't. A peer-reviewed primer strengthens the conversation, not the prescription.

The Frontiers 2026 retrospective IV-NAD+-vs-NR tolerability pilot, the npj Aging crossover RCT on a systems NAD+ supplement, and the May 11 NPR skepticism story — read together, by a physician who prescribes both routes. Mechanism settled, precursor RCT data moderate and growing, IV pharmacokinetics real and under-trialed, longevity endpoint trials still missing. Why Limitless leads with the IV load, and what would change that.

Tesamorelin is named in the literature for more than belly fat. The hepatic-fat data is a randomized signal on a hard endpoint — roughly a one-third relative reduction in liver fat. The cognitive data is one real GHRH trial in mild cognitive impairment, not a settled case. And a third "signal" — a 49% jump in patient search demand — is a market fact, not a medical one. What the 2026 evidence supports past the on-label indication, and what it does not change about how we prescribe.

The internet frames them as rivals — "tesamorelin vs MOTS-c, which wins?" In the clinic that is a category error. Tesamorelin works the GH/IGF-1 axis with FDA approval and randomized, CT-measured visceral-fat data; MOTS-c works AMPK and mitochondrial efficiency with a clean mechanism but zero completed human RCTs. Different levers, opposite ends of the evidence spectrum. The honest reason to use both — and how we match the strength of the recommendation to the strength of the data.

Twelve peptides across two PCAC meetings — seven in July 2026, five more in early 2027 — and eight of them are not on the Limitless menu. KPV, Semax, Epitalon; then GHK-Cu, Melanotan II, LL-37, Dihexa, PEG-MGF. A favorable vote makes a peptide legally compoundable, not clinically warranted. The honest roadmap for each, wave by wave: evidence tier, the menu-addition gate, and whether Limitless would add it.

Companion piece to the tesamorelin brief. Walker 2006 long-term safety, Khorram 1997 and Vittone 1997 efficacy signals, and the specific situations where sermorelin substitutes for tesamorelin in the standing protocol — contraindication, supply gap, cost-sensitivity, lower-magnitude target, cycle transition. Where ipamorelin stacks on top, and what the July 23 PCAC outcomes would change.

A primary-source brief on the five organ systems where low-dose daily 5 mg tadalafil has durable evidence — BPH/LUTS (FDA-approved), endothelial function, exercise capacity in HFpEF and PAH, prostate perfusion, and cognitive perfusion. The mechanism is unified through cGMP. The case for a standing preventative protocol in adult men over 40 is unusually clean — and this is the evidence anchor for it.

The molecule is only half the question; the source is the other half. The three sourcing lanes explained plainly — 503A patient-specific compounding, 503B outsourcing facilities, and the unregulated "research use only" grey market — why Limitless uses only licensed 503A pharmacies, what a per-lot certificate of analysis is, and the single question that separates safe peptide care from a gamble.

The formal comment Limitless filed with the FDA on 2026-05-15, ahead of the July 23–24 Pharmacy Compounding Advisory Committee vote. A physician's case to include BPC-157, TB-500, and MOTS-c on the 503A bulks list — with per-lot CoA, stability data, and written informed-consent conditions attached. Full filed text on the page, signed Joshua Hare, DO. Patient-facing landing →

An FDA-approved GHRH analog with a robust visceral-fat signal, an increasingly clean muscle-area / muscle-density signal, and an emerging cognitive endpoint. Sermorelin sits as alternative. Ipamorelin is conditional on the partner-pharmacy formulary. CJC-1295 is not on the menu — and here is exactly why. The evidence anchor for our May 2026 GH-axis substitution.

A 16-amino-acid peptide encoded inside mitochondrial DNA. The mechanism is biochemically settled — AICAR accumulation, AMPK activation, PGC-1α–driven mitochondrial biogenesis. The March 2026 muscle paper confirms the chain is load-bearing in vivo. The human efficacy trials still do not exist. Why MOTS-c sits in the Limitless standing stack inside that uncertainty, what we tell every patient, and how the July 23 PCAC vote could shift it.

Seven peptides on the agenda — four on day one (BPC-157, KPV, TB-500, MOTS-c), three on day two (DSIP, Epitalon, Semax) — plus a second PCAC meeting already scheduled for early 2027. A public comment window that closes July 22, 2026 (comments by July 9 reach the committee before the vote). What each possible vote — include, exclude, or table — would mean for a Limitless patient, why CJC-1295 is not on this docket, and how to weigh in before the vote, not after.

A three-amino-acid α-MSH fragment with a clean PepT1-mediated mechanism, two decades of consistent murine colitis data, and not a single completed human RCT. Why Limitless is watching but not prescribing — and exactly which conditions would have to be met after the July 23 PCAC vote for that posture to change.

The FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. What it changes for 503B outsourcing facilities, what it does not change for 503A patient-specific compounding, and the three lanes a Limitless patient sees today — including why retatrutide is not one of them.

A physician's response to the 2026 "peptide craze" skepticism — CNN, Eric Topol's Substack, the STAT and The Conversation pieces, the Frontiers in Aging January review. The skeptics are right that marketing has outrun the trials. They are not right that the molecules don't work. Both can be true at once — and the physician's job is to live in that gap honestly. Three evidence tiers, six prescribing rules, and what we deliberately do not prescribe.

5,246 hypogonadal men, mean 33 months on therapy, no signal of MACE, no excess prostate cancer, a small atrial-fibrillation signal worth screening for. The randomized trial that finally settles the cardiovascular safety question — and how it shapes the Limitless approach to hormone optimization.

A pooled five-trial meta-analysis published in 2026 reports a mean −27.7 cm² reduction in visceral adipose tissue and a +1.42 kg increase in lean body mass on standard 2 mg dosing. The signal is consistent across HIV and non-HIV populations, holds up on modern INSTI regimens, and is now coupled to an emerging cognitive endpoint. Here is what the data supports — and what it does not.

BPC-157 returns to the PCAC on July 23, 2026, this time formally evaluated for inclusion on the 503A bulks list. The animal data is voluminous and consistent. The human data is thin but improving. Here is what the dossier in front of the committee actually contains, what the credible mechanisms are, and how Limitless prescribes BPC-157 inside that uncertainty.

The mitochondrial biology is solid. The precursor RCTs (NR, NMN) raise NAD+ and move metabolic markers in expected directions. The IV pharmacokinetic data is unambiguous. The longevity-endpoint trials in humans do not exist. Here is the honest map of what NAD+ does and does not do — and how the Limitless 5×750 mg IV load plus SubQ maintenance protocol is structured around what the data actually supports.

The mechanistic deep-dive companion to the five-systems brief — how PDE5 inhibition with a 17.5-hour half-life molecule sustains cGMP tone downstream of endothelial nitric oxide, what flow-mediated dilation actually measures, and why the surrogate-to-outcome translation matters. Read the five-systems overview first if you haven't.